|
|
|
|
||
Brokerages Anticipate Prothena Co. PLC (PRTA) to Announce -$1.05 EPS10-18-2018
quities research analysts forecast that Prothena Co. PLC (NASDAQ:PRTA) will report ($1.05) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Prothena’s earnings. The highest EPS estimate is ($0.99) and the lowest is ($1.12). Prothena posted earnings per share of ($1.37) during the same quarter last year, which would suggest a positive year-over-year growth rate of 23.4%. The business is expected to announce its next earnings report on Tuesday, November 6th. According to Zacks, analysts expect that Prothena will report full-year earnings of ($4.43) per share for the current year, with EPS estimates ranging from ($4.54) to ($4.28). For the next year, analysts expect that the company will post earnings of ($2.00) per share, with EPS estimates ranging from ($2.70) to ($0.85). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Prothena. Prothena (NASDAQ:PRTA) last issued its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.15. Prothena had a negative net margin of 21,884.38% and a negative return on equity of 46.42%. The business had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.22 million. A number of equities analysts have commented on PRTA shares. Zacks Investment Researchupgraded shares of Prothena from a “sell” rating to a “hold” rating in a research report on Friday, August 10th. BidaskClub upgraded shares of Prothena from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. ValuEngine upgraded shares of Prothena from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 2nd. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $18.00 price target on shares of Prothena in a research report on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $36.67. Large investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. raised its stake in shares of Prothena by 47.7% in the second quarter. Oppenheimer & Co. Inc. now owns 11,455 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 3,700 shares during the last quarter. Raymond James & Associates bought a new position in shares of Prothena in the second quarter worth about $170,000. Xact Kapitalforvaltning AB bought a new position in shares of Prothena in the first quarter worth about $210,000. LPL Financial LLC bought a new position in shares of Prothena in the first quarter worth about $210,000. Finally, Senzar Asset Management LLC bought a new position in shares of Prothena in the second quarter worth about $249,000. Shares of Prothena stock opened at $13.03 on Thursday. Prothena has a twelve month low of $10.43 and a twelve month high of $62.99. The stock has a market cap of $521.07 million, a PE ratio of -3.20 and a beta of 2.93. Prothena Company Profile Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. Featured Story: Asset Allocation, Balancing Your Investments Get a free copy of the Zacks research report on Prothena (PRTA) For more information about research offerings from Zacks Investment Research, visit Zacks.com
|
return to message board, top of board |